DIAGNOSTIC TEST PANEL 558
Narcolepsy
Diagnostic test panel for HLA-DQB1*06:02 and hypocretin/orexin. For suspicion of Narcolepsy.
Indication
Suspicion of Narcolepsy
Sample material
CSF
- Minim. volume: 0,5 mL
EDTA whole blood
- Minim. volume: 3 mL
Transport
Within Sweden
- room temperature
International
- cold
Clinical background
Narcolepsy is a chronic neurological disorder that disrupts the regulation of sleep and wakefulness.
The patients suffer from pronounced sleepiness during the day and disturbed sleep at night. Cataplexy, hallucinations, and sleep paralysis are also common symptoms.
Narcolepsy is classified according to the International Classification of Sleep Disorders (ICSD3) as narcolepsy type 1 (NT1) or 2 (NT2). Narcolepsy type 1 is considered an autoimmune disease where the immune system attacks and destroys the orexin-producing neurons in the hypothalamus.
The level of Orexin in cerebrospinal fluid is reduced at NT1.
Over 95% of all people with NT1 are carriers of HLA-DQB1*06:02.
Patients with NT2 lack cataplexy and have normal levels of orexin/hypocretin. The cause of type 2 is still unknown.
Tests included in panel
Need pricing information?
How to order
This test panel is available worldwide for hospitals, clinics, and physicians.
-
Print and complete the request form
Download the request form. Clearly state the name and phone number of the referring hospital, clinic, or physician. Genetic testing also requires a sigend consent form. -
Prepare your samples
CSF: At least 0.5 mL CSF (polypropylene tubes).
Whole blood: At least 3 mL blood (EDTA tubes).
-
Send samples and request form
Within Sweden
Samples can be sent at room temperature to:
Envelopes and smaller boxes:
Wieslab AB, Box 50117, 20211 Malmö, Sweden
Larger boxes and frozen samples:
Wieslab AB, Lundavägen 151, 21224 Malmö, Sweden
International
Send samples cold to:
Wieslab AB, Lundavägen 151, 21224 Malmö, Sweden
Last updated: 2025-08-18
